Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression

Journal of Clinical Investigation

Volumn 123, Issue 3, 2013, Pages 1157-1175

  Patel, Rachana ^a   Gao, Meiling ^a   Ahmad, Imran ^a,b   Fleming, Janis ^a   Singh, Lukram B ^a   Rai, Taranjit Singh ^b   McKie, Arthur B ^c   Seywright, Morag ^d   Barnetson, Robert J ^d   Edwards, Joanne ^b   Sansom, Owen J ^a   Leung, Hing Y ^a,b  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN; PROTEIN KINASE B; SPROUTY2 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE INACTIVATION; GENE SILENCING; HAPLOINSUFFICIENCY; HUMAN; HUMAN CELL; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION;

ANIMALS; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; ENZYME ACTIVATION; G1 PHASE CELL CYCLE CHECKPOINTS; GENE KNOCKDOWN TECHNIQUES; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, NUDE; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN PHOSPHATASE 2; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; PTEN PHOSPHOHYDROLASE; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; TUMOR BURDEN;

EID: 84874599503     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI63672     Document Type: Article

References (43)

1. Yap TA, Zivi A, Omlin A, de Bono JS. The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol. 2011;8(10):597-610.
2. Taylor BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11-22.
3. Kennedy AL, et al. Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumourigenesis. Mol Cell. 2011;42(1):36-49.
4. Ahmad I, et al. HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer. Proc Natl Acad Sci U S A. 2011;108(39):16392-16397.
5. McKie AB, et al. Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer. Oncogene. 2005;24(13):2166-2174. (Pubitemid 40516583)
6. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550-562.
7. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell. 2008;133(3):403-414. (Pubitemid 351622014)
8. Ross AH, Gericke A. Phosphorylation keeps PTEN phosphatase closed for business. Proc Natl Acad Sci U S A. 2009;106(5):1297-1298.
9. Baker SJ. PTEN enters the nuclear age. Cell. 2007; 128(1):25-28. (Pubitemid 46048899)
10. Song MS, et al. Nuclear PTEN regulates the APCCDH1 tumor-suppressive complex in a phosphataseindependent manner. Cell. 2011;144(2):187-199.
11. Alimonti A, et al. Subtle variations in Pten dose determine cancer susceptibility. Nat Genet. 2010; 42(5):454-458.
12. Trotman LC, et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 2003;1(3):E59.
13. Whang YE, et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A. 1998;95(9):5246-5250. (Pubitemid 28208583)
14. Trotman LC, et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell. 2007; 128(1):141-156. (Pubitemid 46048885)
15. Hacohen N, Kramer S, Sutherland D, Hiromi Y, Krasnow MA. Sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell. 1998;92(2):253-263. (Pubitemid 28073048)
16. Lo TL, et al. 2006. Sprouty and cancer: the first terms report. Cancer Lett. 2006;242(2):141-150. (Pubitemid 44515046)
17. Holgren C, et al. Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: sprouty/c-Met upregulation in human colonic adenocarcinomas. Oncogene. 2010;29(38):5241-5253.
18. Lee CC, et al. Overexpression of sprouty2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesis. Oncogene. 2004;23(30):5193-5202.
19. Guy GR, Jackson RA, Yusoff P, Chow SY. Sprouty proteins: modified modulators, matchmakers or missing links? J Endocrinol. 2009;203(2):191-202.
20. Lao DH, et al. Direct binding of PP2A to Sprouty2 and phosphorylation changes are a prerequisite for ERK inhibition downstream of fibroblast growth factor receptor stimulation. J Biol Chem. 2007; 282(12):9117-9126.
21. Mumby M. PP2A: unveiling a reluctant tumor suppressor. Cell. 2007;130(1):21-24. (Pubitemid 47031327)
22. Junttila MR, et al. CIP2A inhibits PP2A in human malignancies. Cell. 2007;130(1):51-62. (Pubitemid 47039258)
23. Edwin F, Singh R, Endersby R, Baker SJ, Patel TB. The tumor suppressor PTEN is necessary for human Sprouty2-mediated inhibition of cell proliferation. J Biol Chem. 2006;281(8):4816-4822. (Pubitemid 43847743)
24. Gurova KV, et al. Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells. Cancer Res. 2003;63(11):2905-2912. (Pubitemid 36667163)
25. Chang CJ, Mulholland DJ, Valamehr B, Mosessian S, Sellers WR, Wu H. PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression. Mol Cell Biol. 2008; 28(10):3281-3289. (Pubitemid 351657092)
26. Zhao H, Dupont J, Yakar S, Karas M, LeRoith D. PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene. 2004; 23(3):786-794. (Pubitemid 38241279)
27. Finkel T. Signal transduction by reactive oxygen species. J Cell Biol. 2011;194(1):7-15.
28. Al-Khouri AM, Ma Y, Togo SH, Williams S, Mustelin T. Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta. J Biol Chem. 2005;280(42):35195-35202. (Pubitemid 41532706)
29. Seeling JM, Miller JR, Gil R, Moon RT, White R, Virshup DM. Regulation of beta-catenin signaling by the B56 subunit of protein phosphatase 2A. Science. 1999;283(5410):2089-2091.
30. Cerami E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401-404.
31. Ding Z, et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature. 2011;470(7333):269-273.
32. Yeang CH, McCormick F, Levine A. Combinatorial patterns of somatic gene mutations in cancer. FASEB J. 2008;22(8):2605-2622.
33. Planchon SM, Waite KA, Eng C. The nuclear affairs of PTEN. J Cell Sci. 2008;121(pt 3):249-253. (Pubitemid 351356695)
34. Freeman DJ, et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell. 2003;3(2):117-130. (Pubitemid 37443385)
35. Wang H, et al. Allele-specific tumor spectrum in pten knockin mice. Proc Natl Acad Sci U S A. 2010;107(11):5142-5147.
36. Rhee SG, Bae YS, Lee SR, Kwon J. Hydrogen peroxide: a key messenger that modulates protein phosphorylation through cysteine oxidation. Sci STKE. 2000;2000(53):pe1.
37. Trottier G, Boström PJ, Lawrentschuk N, Fleshner NE. Nutraceuticals and prostate cancer prevention: a current review. Nat Rev Urol. 2010;7(1):21-30.
38. Lippman SM, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009;301(1):39-51.
39. He XC, et al. PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat Genet. 2007; 39(2):189-198. (Pubitemid 46184349)
40. Wang S, Garcia AJ, Wu M, Lawson DA, Witte ON, Wu H. Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci U S A. 2006; 103(5):1480-1485. (Pubitemid 43191191)
41. Lesche R, et al. 2002. Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis. 2002;32(2):148-149. (Pubitemid 34211723)
42. Somers KD, et al. Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: efficacy of flt3 ligand immunotherapy. Int J Cancer. 2003;107(5):773-780. (Pubitemid 37339731)
43. van de Wetering M, et al. Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep. 2003; 4(6):609-615.